{"result": "(\"entity\"<|>PARENTERAL NUTRITION<|>EVENT<|>Parenteral nutrition refers to the intravenous administration of nutrients to patients who cannot obtain adequate nutrition through oral or enteral routes.)\n##\n(\"entity\"<|>INTRAVENOUS LIPID EMULSIONS<|>EVENT<|>Intravenous lipid emulsions are fat emulsions administered intravenously, often used in parenteral nutrition for preterm infants.)\n##\n(\"entity\"<|>TOTAL PARENTERAL NUTRITION (TPN)<|>EVENT<|>Total parenteral nutrition (TPN) is a method of feeding that bypasses the gastrointestinal tract, providing all necessary nutrients directly into the bloodstream.)\n##\n(\"entity\"<|>CENTRAL VENOUS CATHETERS<|>EVENT<|>Central venous catheters are medical devices inserted into a large vein to provide long-term access for intravenous therapy, including parenteral nutrition.)\n##\n(\"entity\"<|>CATHETER-RELATED INFECTIONS<|>EVENT<|>Catheter-related infections are infections that occur in patients with central venous catheters, often requiring specific management and prevention strategies.)\n##\n(\"entity\"<|>HOME PARENTERAL NUTRITION<|>EVENT<|>Home parenteral nutrition is a method of providing nutritional support to patients at home through intravenous administration of nutrients.)\n##\n(\"entity\"<|>THROMBOTIC COMPLICATIONS<|>EVENT<|>Thrombotic complications refer to the formation of blood clots in patients with central venous catheters, which can lead to serious health issues.)\n##\n(\"entity\"<|>VASCULAR ACCESS<|>EVENT<|>Vascular access refers to the methods used to access the bloodstream for intravenous therapy, including parenteral nutrition.)\n##\n(\"entity\"<|>INTRAVASCULAR CATHETER-RELATED INFECTION<|>EVENT<|>Intravascular catheter-related infection is an infection associated with the use of catheters for intravenous therapy, requiring careful management.)\n##\n(\"entity\"<|>EVIDENCE-BASED PRACTICES<|>EVENT<|>Evidence-based practices refer to clinical practices that are based on the best available evidence, particularly in the context of parenteral nutrition and catheter management.)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: al JG, Avitzur Y, Wales PW. Peripherally inserted central catheters for long-term parenteral nutrition in infants with intestinal failure. J Pediatr Gastroenterol Nutr. 2013; 56:578-581.\n\n51. Hellbock HJ, Motchnick PA, Ames BN. Toxic hydroperoxides in intravenous lipid emulsions used in preterm infants. Pediatrics. 1993; 91: 83-88.\n\n52. Task Force for the revision of safe practices for Parenteral Nutrition. Safe practices for parenteral nutrition. JPENJ Parent Ent Nutr. 2004; 28: S1-S70.\n\n53. Ball PA. Intravenous in-line filters: filtering the evidence. Curr Opin Clin Nutr Metab Care. 2003; 6: 319-325.\n\n54. Blackmer AB, Partipilo ML. Three-in-One Parenteral Nutrition in Neonates and Pediatric Patients: Risks and Benefits. Nutr Clin Pract. 2015; 30:337-343.\n\n55. Maisonneuve N, Raguso CA, Paolini-Giacobino A, et al. Parenteral nutrition practices in Hospital Pharmacies in Switzerland, France, and Belgium. Nutrition. 2004; 20:528-35.\n\n56. Singh A, Rauch D. Commercial premixed parenteral nutrition and its potential role in pediatrics. Hospital Pediatrics. 2016; 6:34-36.\n\n57. Hwang TL, Lue MC, Chen LL. Early use of cyclic TPN prevents further deterioration of liver functions for the TPN with impaired liver function. Hepatogastroenterology. 2000; 47: 1347-1350.\n\n58. Trissel LA. Handbook of injectable drugs 8th ed. American Society of Hospital Pharmacists. Bethesda. 1994.\n\n59. Staven V, Iqbal H, Wang S, Gronlie I, Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol. 2016; 7. [Epub ahead of print]\n\n60. Gomis Muñoz P, Valero Zanuy MA. Nutrición parenteral. En: Gil A. Tratado de nutrición. 2ª ed. Madrid: EM Panamericana; 2010. p. 143-169.\n\n61. Ireton-Jones C, DeLegge MH, Epperson LA, Alexander J. Management of the home parenteral nutrition patient. Nutr Clin Pract. 2003; 18:310-7.\n\n62. Vanderhoof JA, Young RJ. Overview of considerations for the pediatric patient receiving home parenteral and enteral nutrition. Nutr Clin Pract. 2003; 18:221-6.\n\n63. Trieschmann U, ten F Cate U, Sreeram N. Central venous catheters in children and neonates – what is important? Images Paediatr Cardiol. 2007; 9:1–8.\n\n64. Chwals WJ. Vascular access for home intravenous therapy in children. JPEN J Parenter Enteral Nutr. 2006; 30:S65-9.\n\n65. Murphy PC, Arnold P. Ultrasound-assisted vascular access in children. Contin Educ Anaesth Crit Care Pain 2011; 11:44-9.\n\n66. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Curr Opin Hematol 2003; 10:369-74.\n\n67. Goossens GA. Flushing and locking of venous catheters: available evidence and evidence deficit. Nurs Res Pract 2015; 2015:985686.\n\n68. Vidal E, Sharathkumar A, Glover J, Faustino EV. Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis. J Thromb Haemost. 2014; 12:1096-109.\n\n69. Brandão LR, Shah N, Shah PS. Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. Cochrane Database Syst Rev. 2014; 3:CD005982.\n\n70. Kerner JA, Garcia-Careaga MG, Fisher AA, Poole RL. Treatment of catheter occlusion in pediatric patients. JPEN J Parenter Enteral Nutr. 2006; 30:S73-S81.\n\n71. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the\n---\nTema 55. Nutrición parenteral en el paciente pediátrico: vías y fórmulas 879\n\nInfectious Diseases Society of America. Clin Infect Dis. 2009; 49:1-45.\n\n72. Janum S, Zingg W, Classsen V, Afshari A. Bench-to-bedside review: challenges of diagnosis, care and prevention of central catheter-realted bloodstream infections in children. Crit Care. 2013; 28:238.\n\n73. Germán Díaz M, Moreno Villares JM; Gomis Muñoz P, León Sanz M. Sellado con antibióticos o antisépticos en pacientes pediá\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>AVITZUR Y<|>PERSON<|>Avitzur Y is an author who contributed to the study on peripherally inserted central catheters for long-term parenteral nutrition in infants with intestinal failure.)\n##\n(\"entity\"<|>WALES PW<|>PERSON<|>Wales PW is an author involved in the research on peripherally inserted central catheters for long-term parenteral nutrition in infants with intestinal failure.)\n##\n(\"entity\"<|>HELLBOCK HJ<|>PERSON<|>Hellbock HJ is an author who studied toxic hydroperoxides in intravenous lipid emulsions used in preterm infants.)\n##\n(\"entity\"<|>MOTCHNICK PA<|>PERSON<|>Motchnick PA is an author who collaborated on the research regarding toxic hydroperoxides in intravenous lipid emulsions.)\n##\n(\"entity\"<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>ORGANIZATION<|>The Task Force is responsible for revising and establishing safe practices for parenteral nutrition.)\n##\n(\"entity\"<|>BALL PA<|>PERSON<|>Ball PA is an author who discussed intravenous in-line filters and their evidence in clinical nutrition.)\n##\n(\"entity\"<|>BLACKMER AB<|>PERSON<|>Blackmer AB is an author who analyzed the risks and benefits of three-in-one parenteral nutrition in neonates and pediatric patients.)\n##\n(\"entity\"<|>MAISONNEUVE N<|>PERSON<|>Maisonneuve N is an author who researched parenteral nutrition practices in hospital pharmacies across Switzerland, France, and Belgium.)\n##\n(\"entity\"<|>SINGH A<|>PERSON<|>Singh A is an author who explored the role of commercial premixed parenteral nutrition in pediatrics.)\n##\n(\"entity\"<|>HWANG TL<|>PERSON<|>Hwang TL is an author who studied the early use of cyclic TPN in preventing liver function deterioration in pediatric patients.)\n##\n(\"entity\"<|>TRISSEL LA<|>PERSON<|>Trissel LA is an author of the Handbook of Injectable Drugs, a reference for healthcare professionals.)\n##\n(\"entity\"<|>GOMIS MUÑOZ P<|>PERSON<|>Gomis Muñoz P is an author who contributed to the book on parenteral nutrition.)\n##\n(\"entity\"<|>IRETON-JONES C<|>PERSON<|>Ireton-Jones C is an author who discussed the management of home parenteral nutrition patients.)\n##\n(\"entity\"<|>VANDERHOOF JA<|>PERSON<|>Vanderhoof JA is an author who provided an overview of considerations for pediatric patients receiving home parenteral and enteral nutrition.)\n##\n(\"entity\"<|>TRIESCHMANN U<|>PERSON<|>Trieschmann U is an author who discussed the importance of central venous catheters in children and neonates.)\n##\n(\"entity\"<|>MURPHY PC<|>PERSON<|>Murphy PC is an author who researched ultrasound-assisted vascular access in children.)\n##\n(\"entity\"<|>JOURNEYCAKE JM<|>PERSON<|>Journeycake JM is an author who studied thrombotic complications of central venous catheters in children.)\n##\n(\"entity\"<|>GOOSSENS GA<|>PERSON<|>Goossens GA is an author who discussed flushing and locking of venous catheters.)\n##\n(\"entity\"<|>VIDAL E<|>PERSON<|>Vidal E is an author who conducted a systematic review on central venous catheter-related thrombosis in children.)\n##\n(\"entity\"<|>BRANDÃO LR<|>PERSON<|>Brandão LR is an author who researched low molecular weight heparin for preventing catheterization-related thrombosis in children.)\n##\n(\"entity\"<|>KERNER JA<|>PERSON<|>Kerner JA is an author who studied the treatment of catheter occlusion in pediatric patients.)\n##\n(\"entity\"<|>MERMEL LA<|>PERSON<|>Mermel LA is an author of clinical practice guidelines for the diagnosis and management of intravascular catheter-related infections.)\n##\n(\"entity\"<|>JANUM S<|>PERSON<|>Janum S is an author who reviewed challenges in the diagnosis and care of central catheter-related bloodstream infections in children.)\n##\n(\"relationship\"<|>AVITZUR Y<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Avitzur Y is likely involved in the research and practices related to parenteral nutrition as part of the task force<|>5)\n##\n(\"relationship\"<|>WALES PW<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Wales PW is likely involved in the research and practices related to parenteral nutrition as part of the task force<|>5)\n##\n(\"relationship\"<|>HELLBOCK HJ<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Hellbock HJ is likely involved in the research and practices related to parenteral nutrition as part of the task force<|>5)\n##\n(\"relationship\"<|>MOTCHNICK PA<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Motchnick PA is likely involved in the research and practices related to parenteral nutrition as part of the task force<|>5)\n##\n(\"relationship\"<|>BALL PA<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Ball PA's work on intravenous in-line filters may contribute to the safe practices for parenteral nutrition<|>4)\n##\n(\"relationship\"<|>BLACKMER AB<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Blackmer AB's analysis of parenteral nutrition risks and benefits may inform the task force's guidelines<|>4)\n##\n(\"relationship\"<|>MAISONNEUVE N<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Maisonneuve N's research on parenteral nutrition practices may be relevant to the task force's work<|>4)\n##\n(\"relationship\"<|>SINGH A<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Singh A's exploration of commercial premixed parenteral nutrition may inform safe practices<|>4)\n##\n(\"relationship\"<|>HWANG TL<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Hwang TL's study on cyclic TPN may contribute to the task force's guidelines<|>4)\n##\n(\"relationship\"<|>TRISSEL LA<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Trissel LA's handbook may serve as a reference for the task force<|>4)\n##\n(\"relationship\"<|>GOMIS MUÑOZ P<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Gomis Muñoz P's work on parenteral nutrition may be relevant to the task force's guidelines<|>4)\n##\n(\"relationship\"<|>IRETON-JONES C<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Ireton-Jones C's management strategies for home parenteral nutrition may inform the task force<|>4)\n##\n(\"relationship\"<|>VANDERHOOF JA<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Vanderhoof JA's overview of pediatric considerations may be relevant to the task force's work<|>4)\n##\n(\"relationship\"<|>TRIESCHMANN U<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Trieschmann U's insights on central venous catheters may inform the task force's guidelines<|>4)\n##\n(\"relationship\"<|>MURPHY PC<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Murphy PC's research on vascular access may contribute to the task force's practices<|>4)\n##\n(\"relationship\"<|>JOURNEYCAKE JM<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Journeycake JM's study on thrombotic complications may inform the task force's guidelines<|>4)\n##\n(\"relationship\"<|>GOOSSENS GA<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Goossens GA's work on catheter flushing may be relevant to the task force's practices<|>4)\n##\n(\"relationship\"<|>VIDAL E<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Vidal E's systematic review may inform the task force's guidelines on catheter-related issues<|>4)\n##\n(\"relationship\"<|>BRANDÃO LR<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Brandão LR's research on heparin use may be relevant to the task force's practices<|>4)\n##\n(\"relationship\"<|>KERNER JA<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Kerner JA's study on catheter occlusion may inform the task force's guidelines<|>4)\n##\n(\"relationship\"<|>MERMEL LA<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Mermel LA's clinical practice guidelines may serve as a reference for the task force<|>4)\n##\n(\"relationship\"<|>JANUM S<|>TASK FORCE FOR THE REVISION OF SAFE PRACTICES FOR PARENTERAL NUTRITION<|>Janum S's review of challenges may inform the task force's guidelines<|>4)\n<|COMPLETE|>"}]}